Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma. - Pham TD; Becker JH; Metropulos AE; Mubin N; Spaulding C; Bentrem DJ; Munshi HG (BMC cancer, 2024)